Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Immunotherapy and Precision Oncology|August 29, 2022
Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University ExperienceDylan J Martini, T Anders Olsen, Subir Goyal, et al.
Frontiers in Oncology|July 5, 2021
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint BlockadeT Anders Olsen, Dylan J Martini, Subir Goyal, et al.
Frontiers in Oncology|July 26, 2021
Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint InhibitorsDylan J Martini, T Anders Olsen, Subir Goyal, et al.
Clinical Genitourinary Cancer|December 19, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma PatientsDylan J Martini, Sean T Evans, Yuan Liu, et al.
The Oncologist|June 22, 2021
Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint InhibitorsDylan J Martini, Subir Goyal, Yuan Liu, et al.
The Oncologist|August 3, 2021
Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint InhibitorsDylan J Martini, Julie M Shabto, Subir Goyal, et al.
Urologic Oncology|October 28, 2025
Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE studyTanya Jindal, Cindy Y Jiang, Omar Alhalabi, et al.
The Oncologist|October 7, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative studyCindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, et al.
Cancer Medicine|October 1, 2025
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE StudyAmanda Nizam, Charles B Nguyen, Jinju Li, et al.
Pageof 2